Goldman Sachs’s NantHealth, Inc NH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-5,733
Closed -$36K 6755
2022
Q2
$36K Buy
+5,733
New +$53.5K ﹤0.01% 6092
2021
Q3
Sell
-1,768
Closed -$61K 6642
2021
Q2
$61K Buy
+1,768
New +$70.3K ﹤0.01% 6041
2020
Q4
Sell
-2,968
Closed -$104K 5799
2020
Q3
$104K Buy
+2,968
New +$167K ﹤0.01% 5085
2020
Q2
Sell
-2,700
Closed -$64K 5571
2020
Q1
$64K Buy
+2,700
New +$64.6K ﹤0.01% 5009
2019
Q3
Sell
-5,356
Closed -$42K 5454
2019
Q2
$42K Buy
+5,356
New +$54.5K ﹤0.01% 5024
2019
Q1
Sell
-10,635
Closed -$87K 5546
2018
Q4
$87K Buy
10,635
+7,546
+244% +$132K ﹤0.01% 5018
2018
Q3
$73K Sell
3,089
-1,456
-32% -$55.4K ﹤0.01% 5218
2018
Q2
$226K Sell
4,545
-151
-3% -$7.47K ﹤0.01% 4945
2018
Q1
$215K Sell
4,696
-1,690
-26% -$84.8K ﹤0.01% 4963
2017
Q4
$292K Sell
6,386
-2,762
-30% -$146K ﹤0.01% 5193
2017
Q3
$565K Sell
9,148
-2,159
-19% -$126K ﹤0.01% 5013
2017
Q2
$717K Buy
11,307
+5,402
+91% +$299K ﹤0.01% 4762
2017
Q1
$439K Sell
5,905
-309
-5% -$34.4K ﹤0.01% 5147
2016
Q4
$927K Buy
6,214
+5,137
+477% +$909K ﹤0.01% 4524
2016
Q3
$212K Buy
+1,077
New +$198K ﹤0.01% 5780

Other funds holding NH

Goldman Sachs's NH Position: Q3 2022 in Review

Goldman Sachs sold out of NantHealth, Inc (NH) in Q3 2022, closing a stake of 5,733 shares — an estimated $36K sold.

Goldman Sachs first reported a position in NH in Q3 2016 and held it in 15 quarters. The position peaked at $927K in Q4 2016. 38 funds tracked by Wall St. Rank hold NH as of Q3 2022.

  • Goldman Sachs reported no remaining NantHealth, Inc position as of Q3 2022 after selling out during the quarter.
  • Goldman Sachs sold 5,733 NantHealth, Inc shares in Q3 2022, an estimated $36K.
  • Goldman Sachs first reported a position in NantHealth, Inc in Q3 2016 and held it in 15 quarters.
  • Goldman Sachs's NantHealth, Inc position peaked at $927K in Q4 2016.
  • 38 funds tracked by Wall St. Rank held NantHealth, Inc as of Q3 2022.

Based on Goldman Sachs's 13F filing for Q3 2022, filed 14 Nov 2022.